Active substance
Mebendazole
- SFDA 8
- US FDA 3
- Health Canada 1
- US price lines 1
- NHS prices 2
- WHO EML 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BENDAZOLE 100 MG TAB | 100 mg | Tablet · Oral use | 6 Blister | SAR 5.45 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Valid |
| PARAZOLE 100MG TABLET | 100 mg | Tablet · Oral use | 6 Blister | SAR 6.80 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| VERMOX 100MG TABLET | 100 mg | Tablet · Oral use | 6 Blister | SAR 9.50 | Generic · Prescription | JANSSEN-CILAG | Valid |
| VERMOX SUSPN 2% | 2 % | Oral suspension · Oral use | 1 Bottle | SAR 12.30 | NCE · Prescription | JANSSEN-CILAG | Valid |
| PARAZOLE(MEBZOL) 100MG-5ML SUSPENSION | 2 % | Oral suspension · Oral use | 1 Bottle | SAR 7.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| VERMOX 500MG TAB | 500 mg | Tablet · Oral use | 1 Blister | SAR 5.90 | NCE · Prescription | JANSSEN PHARMACEUTICA N.V | Withdrawn by MAH · Not Marketed |
| WORMAZOL SUSP 2% | 2 % | Oral suspension · Oral use | 1 Bottle | SAR 8.35 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| WORMAZOLE CHEWABLE 100MG TAB | 100 mg | Chewable tablet · Oral use | 6 Blister | SAR 7.55 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ASCARIASIS; HOOKWORM; PINWORM (ENTEROBIASIS, OXYURIASIS, THREADWORM); TRICHINELLOSIS (ALSO KNOWN AS TRICHINOSIS); TRICHURIASIS (ALSO KNOWN AS WHIPWORM INFECTION)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| EMVERM | 100MG | tablet, chewable · oral | IMPAX LABS INC | Prescription | 4 Jan 1995 |
| VERMOX | 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, chewable · oral | JANSSEN PHARMS | Discontinued | 28 Jun 1974 |
| VERMOX | 500MG | tablet, chewable · oral | JANSSEN PHARMS | Discontinued | 19 Oct 2016 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VERMOX | 00556734 | 100 MG | TABLET · ORAL | JANSSEN INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | EMVERM 100 MG TABLET CHEW | $712.46855 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Mebendazole 100mg chewable tablets sugar free | £1.34 | 6 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Mebendazole 100mg/5ml oral suspension | £1.55 | 30 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.1.1. Intestinal anthelminthics · core
Hookworm diseases; Trichuriasis; Ascariasis; Enterobiasis
Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable) - 6.1.4. Cysticidal medicines · complementary
Other specified echinococcosis
Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
Safety signals and safety-related labeling changes
- US FDA 20 Sep 2021 VERMOX — safety-related labeling change
Labeling sections changed: Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Jun 2017 VERMOX — safety-related labeling change
Labeling sections changed: Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.